Generic Enjuvia Availability

Enjuvia is a brand name of conjugated estrogens, approved by the FDA in the following formulation(s):

ENJUVIA (estrogens, conjugated synthetic b - tablet;oral)

  • Manufacturer: TEVA WOMENS
    Approval date: May 10, 2004
    Strength(s): 0.625MG, 1.25MG [RLD]
  • Manufacturer: TEVA WOMENS
    Approval date: December 20, 2004
    Strength(s): 0.3MG, 0.45MG
  • Manufacturer: TEVA WOMENS
    Approval date: April 27, 2007
    Strength(s): 0.9MG

Has a generic version of Enjuvia been approved?

No. There is currently no therapeutically equivalent version of Enjuvia available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Enjuvia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
    Patent 6,660,726
    Issued: December 9, 2003
    Inventor(s): Edward N.; Hill & Frederick D.; Sancilio & Robert R.; Whittle
    Assignee(s): Endeavor Pharmaceuticals
    Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an &agr; or a &bgr; orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Patent expiration dates:
    • March 8, 2021
      ✓ 
      Patent use: TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 8, 2021
      ✓ 
      Patent use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
    Patent 6,855,703
    Issued: February 15, 2005
    Inventor(s): Hill; Edward N. & Leonard; Thomas W. & Sancilio; Frederick D. & Schlipp; Katherin M. & Shirazi; Dean G. & Whittle; Robert R.
    Assignee(s): Endeavor Pharmaceuticals
    A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated Δ8,9-dehydroestrone, conjugated 17α-estradiol, conjugated 17α-dihydroequilin, conjugated 17β-dihydroequilin, conjugated 17β-estradiol, conjugated equilenin, conjugated 17α-dihydroequilenin, and conjugated 17β-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.
    Patent expiration dates:
    • February 12, 2021
      ✓ 
      Patent use: TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 12, 2021
      ✓ 
      Patent use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
      ✓ 
      Drug substance
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)